Modality
Degrader
MOA
CD3xCD20
Target
FXIa
Pathway
Sphingolipid
ThymomaHuntington's
Development Pipeline
Preclinical
~Dec 2019
→ ~Mar 2021
Phase 1
Jun 2021
→ May 2029
Phase 1Current
NCT05877527
2,649 pts·Thymoma
2021-06→2029-05·Not yet recruiting
2,649 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-273.2y awayInterim· Thymoma
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Not yet…
Catalysts
Interim
2029-05-27 · 3.2y away
Thymoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05877527 | Phase 1 | Thymoma | Not yet recr... | 2649 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT |